GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDING CO., LTD. Financials Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.
Equities
874
CNE100000387
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.15 HKD | -2.94% |
|
+0.65% | +6.44% |
| Apr. 26 | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 18 | Baiyunshan Pharmaceutical's 2023 Profit Rises 2% | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 55,277 | 44,624 | 52,112 | 46,283 | 44,609 | 50,172 | - | - |
| Enterprise Value (EV) 1 | 42,910 | 34,153 | 39,162 | 34,667 | 34,672 | 30,995 | 27,710 | 25,168 |
| P/E ratio | 12.1 x | 8.93 x | 7.99 x | 8.33 x | 7.92 x | 8 x | 8.29 x | 10.6 x |
| Yield | 2.48% | 3.36% | 3.76% | 3.6% | 3.79% | 3.75% | 3.98% | - |
| Capitalization / Revenue | 0.85 x | 0.72 x | 0.76 x | 0.65 x | 0.59 x | 0.62 x | 0.59 x | 0.55 x |
| EV / Revenue | 0.66 x | 0.55 x | 0.57 x | 0.49 x | 0.46 x | 0.38 x | 0.32 x | 0.28 x |
| EV / EBITDA | 9.17 x | 8.34 x | 7.46 x | 6.15 x | 5.93 x | 4.75 x | 4.4 x | 4.13 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 1.6 x | 1 x | 1.02 x | 1.03 x | 0.92 x | - | 0.84 x | 0.78 x |
| Nbr of stocks (in thousands) | 1,625,791 | 1,625,791 | 1,625,791 | 1,625,791 | 1,625,791 | 1,625,791 | - | - |
| Reference price 2 | 23.77 | 16.01 | 18.29 | 20.31 | 19.77 | 21.46 | 21.46 | 21.46 |
| Announcement Date | 3/31/20 | 3/18/21 | 3/18/22 | 3/17/23 | 3/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 64,952 | 61,674 | 69,014 | 70,788 | 75,515 | 81,088 | 85,609 | 90,933 |
| EBITDA 1 | 4,681 | 4,097 | 5,249 | 5,639 | 5,842 | 6,521 | 6,301 | 6,092 |
| EBIT 1 | 4,055 | 3,672 | 4,786 | 5,074 | 5,121 | 5,464 | 5,426 | 5,676 |
| Operating Margin | 6.24% | 5.95% | 6.93% | 7.17% | 6.78% | 6.74% | 6.34% | 6.24% |
| Earnings before Tax (EBT) 1 | 4,129 | 3,739 | 4,723 | 5,043 | 5,110 | 5,564 | 5,681 | 5,646 |
| Net income 1 | 3,189 | 2,915 | 3,720 | 3,967 | 4,056 | 4,350 | 4,436 | 4,415 |
| Net margin | 4.91% | 4.73% | 5.39% | 5.6% | 5.37% | 5.36% | 5.18% | 4.86% |
| EPS 2 | 1.961 | 1.793 | 2.288 | 2.440 | 2.495 | 2.682 | 2.590 | 2.020 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.5890 | 0.5380 | 0.6870 | 0.7320 | 0.7490 | 0.8046 | 0.8535 | - |
| Announcement Date | 3/31/20 | 3/18/21 | 3/18/22 | 3/17/23 | 3/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 18,342 | 18,214 | 17,331 | 22,946 | 19,626 | 19,489 | 18,544 | 24,762 | 21,000 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | 1,909 | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/27/23 | 8/18/23 | 10/30/23 | 3/15/24 | 4/26/24 | - | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 12,367 | 10,471 | 12,950 | 11,616 | 9,936 | 19,176 | 22,461 | 25,003 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 13.9% | 11.6% | 12.8% | 13% | 12.1% | 11.9% | 10.8% | 10% |
| ROA (Net income/ Total Assets) | 5.89% | 5% | 5.91% | 5.63% | 5.29% | 5.3% | 5.3% | 5.4% |
| Assets 1 | 54,187 | 58,328 | 62,939 | 70,392 | 76,623 | 82,080 | 83,707 | 81,757 |
| Book Value Per Share | 14.90 | 16.10 | 17.90 | 19.70 | 21.50 | - | 25.70 | 27.70 |
| Cash Flow per Share | - | 0.3600 | - | - | 2.520 | - | - | - |
| Capex 1 | 2,399 | 870 | 1,248 | 1,382 | 1,615 | 1,295 | 1,384 | - |
| Capex / Sales | 3.69% | 1.41% | 1.81% | 1.95% | 2.14% | 1.6% | 1.62% | - |
| Announcement Date | 3/31/20 | 3/18/21 | 3/18/22 | 3/17/23 | 3/15/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
21.46
CNY
Average target price
22.14
CNY
Spread / Average Target
+3.14%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.44% | 7.04B | |
| +37.78% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +19.94% | 332B | |
| +5.14% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.32% | 169B |
- Stock Market
- Equities
- 874 Stock
- Financials Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.
